# Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer

> **NCT01998347** · PHASE3 · WITHDRAWN · sponsor: **Shantou University Medical College**

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Paclitaxel liposome
- **DRUG:** Cisplatin
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT01998347
- **Lead sponsor:** Shantou University Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-11
- **Primary completion:** 2017-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** slow enrollment
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01998347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01998347, "Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01998347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*